West Pharmaceutical Stock Sinks On Weaker Than Expected 2025 Guidance

1. WST reported Q4 EPS of $1.82, beating estimates of $1.72. 2. Sales of $748.8 million surpassed forecasts of $740.47 million. 3. 2025 EPS guidance of $6.00-$6.20 is below consensus of $7.44. 4. High-Value Products segment accounts for 74% of net sales. 5. Analysts predict low- to mid-teens earnings growth, delayed until mid-2025.